Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

908
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
908
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

782
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
782
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

461
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
461
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

414
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
414
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

1.0K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Potential role of tirzepatide, a dual GLP-1 and GIP receptor agonist, for preventive treatment of migraine: A case series.

Headache·2026
Same author

Weight loss with atogepant in the long-term treatment of migraine: An interim analysis of a safety endpoint from a phase 3, multicenter, open-label, 156-week extension study.

Headache·2026
Same author

Long-Term Reductions in Headache Frequency, Severity, and Disability with Eptinezumab in Adults with Chronic Migraine: Results from the PREVAIL Trial.

Pain and therapy·2026
Same author

Focus on migraine prodrome: what should clinicians know?

Current opinion in neurology·2026
Same author

Safety, tolerability, and efficacy of atogepant added to onabotulinumtoxinA for the preventive treatment of chronic migraine: A phase 3, multicenter, 24-week, open-label study.

Cephalalgia : an international journal of headache·2026
Same author

Long-Term Improvements Following Initial Migraine Response in Eptinezumab-Treated Participants With Migraine for Whom 2-4 Prior Preventive Treatments Have Failed.

European journal of neurology·2026

Related Experiment Video

Updated: Nov 4, 2025

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.4K

Acute Migraine Treatment.

Jessica Ailani

    Continuum (Minneapolis, Minn.)
    |May 28, 2021
    PubMed
    Summary
    This summary is machine-generated.

    Effective acute migraine treatment involves a combination of approaches, including new medications and neuromodulation devices. These therapies target specific migraine pathways for precise and effective relief.

    More Related Videos

    Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders
    05:49

    Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders

    Published on: November 1, 2024

    1.1K
    Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache
    05:40

    Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

    Published on: July 29, 2021

    8.8K

    Related Experiment Videos

    Last Updated: Nov 4, 2025

    3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
    10:39

    3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

    Published on: June 2, 2014

    18.4K
    Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders
    05:49

    Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders

    Published on: November 1, 2024

    1.1K
    Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache
    05:40

    Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

    Published on: July 29, 2021

    8.8K

    Area of Science:

    • Neurology
    • Medical Devices
    • Pharmacology

    Background:

    • Migraine is a debilitating neurological condition characterized by moderate to severe pain and associated symptoms.
    • Acute attack treatment is essential for all individuals experiencing migraine.
    • Treatment options encompass behavioral strategies, non-specific medications, migraine-specific drugs, and neuromodulation.

    Purpose of the Study:

    • To review current evidence-based therapies for acute migraine.
    • To highlight recent advancements in acute migraine treatment options.

    Main Methods:

    • Review of best-level evidence for acute migraine therapies.
    • Discussion of newly approved medications and FDA-cleared neuromodulation devices.

    Main Results:

    • Four neuromodulation devices have received US Food and Drug Administration (FDA) clearance for acute migraine treatment.
    • Three new medications with novel mechanisms of action have been approved by the FDA.
    • These advancements offer targeted care with potentially fewer side effects.

    Conclusions:

    • A combination of therapeutic tools, including new medications and neuromodulation, can provide effective acute migraine management.
    • Precision medicine approaches focusing on migraine-specific pathways are advancing treatment efficacy.